Insulin-like growth factor-I (IGF-I) plays an important role in regulating vascular smooth muscle cell (VSMC) proliferation, directed migration, differentiation, and apoptosis. The signaling mechanisms used by IGF-I to elicit these actions, however, are not well defined. In this study, we examined the role(s) of protein kinase C (PKC) in mediating the IGF-I actions in cultured porcine VSMCs. Out of the eleven known members of PKC family, PKC-␣, -␤I, -⑀, -, -, , and -, were detectable by Western immunoblot analysis in these cells. Further analysis indicated that the subcellular distribution of several PKC isoforms is regulated by IGF-I. While IGF-I stimulated membrane translocation of PKC-, -⑀, and -and regulated the cytosolic levels of PKC-␤I, it had no such effect on PKC-␣ and -. To examine whether PKC activation is required for the IGF-I-regulated biological responses, phorbol myristate acetate (PMA) and GF109203X were used to down-regulate or inhibit PKC activity. Both PMA (1 M) and GF109203X (20 M) nearly completely suppressed the total PKC activity after a 30-min incubation (Ͼ 90%), and this inhibition lasted for at least 24 h. Down-regulation or inhibition of PKC activity abolished the IGF-I-induced DNA synthesis, migration and IGFBP-5 gene expression. In contrast, the IGFBP-5 expression induced by forskolin was unaffected by PKC down-regulation or inhibition, suggesting that PKC activation is required for the IGF-regulated but not the cAMPregulated events. Because the actions of IGF-I on DNA synthesis and IGFBP-5 gene expression in VSMCs have been shown to be mediated through the phosphatidylinositol 3-kinase (PI3 kinase) signaling pathway in porcine VSMCs, the potential role of PKC in IGF-I-induced activation of PI3 kinase and PKB/Akt were examined. Treatment with either PMA or GF109203X did not significantly affect the effects of IGF-I on PI3 kinase activation or PKB/Akt phosphorylation. These results indicated that PKC-␤I, -, -⑀, and -may play an essential role(s) in IGF-I regulation of VSMC migration, DNA synthesis and gene expression, and that these PKC isoforms may either act independently of the PI3 kinase pathway or act further downstream of PKB/Akt in the IGF signaling network. (Endocrinology 140: [4622][4623][4624][4625][4626][4627][4628][4629][4630][4631][4632] 1999) 
I
NSULIN-LIKE growth factor-I (IGF-I), structurally related to IGF-II and proinsulin, is a plieotropic hormone/ growth factor that plays an important role in regulating vascular smooth muscle (VSMC) growth, migration, differentiation, and apoptosis (1, 2) . These biological actions of IGF-I are mediated by the IGF-I receptor (IGF-IR), a transmembrane tyrosine kinase that is abundantly expressed in VSMCs. Reducing the IGF-IR numbers using antisense approaches suppresses the proliferative responses of VSMCs to IGF-I (3, 4) . Likewise, selective blockage of the IGF-IR with a specific antibody inhibits IGF-I-stimulated cell proliferation and DNA synthesis (5) . The actions of IGF-I are further modulated by a family of high-affinity binding proteins (IGFBPs). Studies using human, porcine, bovine, and rat VSMCs have shown that VSMCs secrete several IGFBPs, including IGFBP-4 and IGFBP-5 (6 -12) . In previous studies, we as well as others have found that IGF-I down-regulates IGFBP-4 levels by activation of its proteolysis (7, 10, 13) , whereas it increases IGFBP-5 levels by stimulating the IG-FBP-5 gene transcription in cultured porcine VSMCs (11, 13) . When added to VSMC cultures, exogenous IGFBP-5 potentiates IGF-I-stimulated DNA synthesis, whereas IGFBP-4 acts as an inhibitor of IGF-I action (13) . These findings suggest that an IGF-I-IGFBP regulatory loop exists in the local vascular environments and that these IGFBPs may play important role(s) in determining VSMC responses to IGF-I by modulating its interaction with the IGF-IR.
While it is known that the IGF-I actions on VSMC growth, migration, differentiation, and apoptosis are mediated through the IGF-IR, it is not clear how one receptor can mediate these diverse, sometimes even mutually exclusive, cellular responses to the same ligand. Studies using model systems (i.e. various tumor or transformed cell lines) indicate that one of the earliest steps in IGF-IR signaling is the phosphorylation of a number of signaling molecules such as insulin receptor substrate(IRS)-1 or -2, Shc, Grb2, and Grb10 (14) . These molecules then interact with SH2 domain-containing proteins, including the Grb2/SOS and phosphatidylinositol 3-kinase (PI3 kinase), resulting in activation of the ras-raf-MEK-MAPK (mitogen-activated protein kinase) and PI3 kinase signaling pathways, respectively. Activation of the MAPK pathway is critical for cell proliferation, whereas the PI3 kinase pathway is considered to be responsible for mediating the metabolic and antiapoptotic actions of IGF-I. It should be emphasized that intracellular signaling pathways induced by a specific receptor is highly cell-type specific. Diploid, normal VSMCs in culture, which are untransformed, may respond differently than 3T3 cells or other immortalized cell lines often used for signal transduction studies (15) . Thus, observations of IGF actions made in immortalized cell lines may not be applicable to primary VSMCs. Indeed, previous studies using cultured bovine and human VSMCs indicated that IGF-I neither stimulated MAPK activity nor elevated intracellular cAMP levels in these cells (16, 17) . Using primary cultures of porcine VSMCs, we have recently shown that while IGF-I activates both the PI3 kinase and MAPK signaling cascades, inhibition of PI3 kinase activation, but not that of MAPK, abolishes the IGF-I-stimulated IGFBP-5 gene expression (18) . These results suggest that, unlike those observations made in tumor cells, activation of PI3 kinase rather than MAPK is required for IGF-I action in primary, diploid VSMCs. Despite this progress, many important questions still remain. For instance, are other signaling components/pathways involved in IGF signaling in VSMCs ? If so, what are their relationships with the PI3 kinase and MAPK signaling pathways? To understand how the IGF-IR can mediate the diverse actions of IGF-I in VSMCs, the intracellular signaling network initiated from the IGF-IR must be understood in greater detail.
In this study, we report that several protein kinase C (PKC) isoforms are expressed in cultured procine VSMCs and their subcellular distribution is regulated by IGF-I. Furthermore, down-regulation or inhibition of PKC inhibited IGF-I-stimulated VSMC DNA synthesis, migration, and gene expression. These data indicate that these PKC isoforms may be essential signaling intermediates for IGF-I actions in porcine VSMCs in addition to the previously identified PI3 kinase and MAPK.
Materials and Methods Materials
All chemicals and reagents were purchased from Sigma (St. Louis, MO) unless noted otherwise. The antibody against IRS-1 was purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). Phospho-specific and control antibodies for MAPK and PKB/Akt were purchased from New England Biolabs, Inc. (Beverly, MA). Antibodies for various PKC isoforms were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Horseradish peroxidase-linked antirabbit or antimouse antibodies, rainbow molecular weight markers, [ 32 P]-ATP and -dCTP were from Amersham Pharmacia Biotech (Amersham, UK). Human IGF-I was obtained from GroPep Pty. Ltd. (Adelaide, Australia). The PI3 kinase inhibitor, LY294002, was purchased from BIOMOL (Plymouth Meeting, PA). FBS, DMEM with high glucose, penicillin-streptomycin, and the PKC-specific peptide substrate, Ac-MBP (4 -14), were purchased from Life Technologies, Inc. (Grand Island, NY). Cell permeable PKC inhibitor, GF109203X, and the PI3 kinase inhibitor, wortmannin, were purchased from Calbiochem (La Jolla, CA). P-81 phosphocellulose membrane was purchased from Whatman Inc. (Clifton, NJ). Trypsin was obtained from Roche Molecular Biochemicals (Indianapolis, IN).
Cell culture
Porcine aortic smooth muscle cells (VSMC) were isolated from the thoracic aorta of a 3-week-old piglet. The cells were grown in DMEM supplemented with 4 mm glutamine, penicillin (100 U/ml), and streptomycin (100 g/ml) plus 10% FBS at 37 C in 10-cm dishes (Falcon, Becton Dickinson and Co. Labware, Franklin Lakes, NJ). Medium was changed every fourth day until cells became confluent. For stimulation experiments, cells were kept in serum-free medium (SFM) for 18 -24 h and then treated with indicated growth factors for the various times indicated. The protein concentration of the cleared lysates was determined by the copper-bicinchoninic acid method with a kit from Pierce Chemical Co. (Rockford, IL).
Cell fractionation
Preparation of cytosolic and membrane fractions was as described previously (19) with slight modification. Briefly, cells were treated with IGF-I or PMA for indicated periods of times after overnight serum-free medium starvation. After treatments, cells were scraped in buffer A (25 mm Tris-HCl, pH 7.5, containing 250 mm sucrose, 0.5 mm EDTA, 0.5 mm EGTA, 20 g/ml leupeptin, 2 g/ml aprotinin, and 1 mm phenylmethylsulfonyl fluoride (PMSF)), sheared by passages through a 26.5 gauge needle, and centrifuged at 100,000 ϫ g for 1 h. The supernatant was designated as the cytosolic fraction. The pellet was extracted with buffer B (20 mm Tris-HCl, pH 7.5, containing 1% SDS, 150 mm NaCl, 1 mm EDTA, 1 mm EGTA,, 20 g/ml leupeptin, 2 g/ml aprotinin, and 1 mm PMSF), and centrifuged at 30,000 ϫ g for 20 min. The supernatant was saved as the membrane fraction. Protein concentrations of the samples were determined by the copper-bicinchoninic acid method using a kit from Pierce Chemical Co. (Rockford, IL).
Western immunoblot analysis
For anti-PKB/Akt blotting, cells were lysed with lysis buffer (65 mm Tris, 0.2 m NaCl, 0.5% IGEPAL CA-630, 0.1% BSA, 5 mm EDTA, 1 mm PMSF, 5 g/ml leupeptin, 5 g/ml aprotinin). Equal amounts of lysates were separated by 12.5% SDS-PAGE and transferred to Immunobilon P membrane (0.45 m pore size, Millipore Corp., Bedford, MA). The membranes were blocked in a Tris-buffered saline-Tween 20 (TBST) containing 3% BSA (Fisher Scientific, Pittsburgh, PA) and subsequently incubated with a 1:1000 dilution of either phospho-specific PKB/Akt antibody or a control antibody overnight at 4 C. After washing with TBST, the blots were incubated with a horseradish peroxidase-linked secondary antibody for 2 h. Again, the blots were washed, and enhanced chemiluminescence was performed according to the manufacturer's instructions (Amersham Pharmacia Biotech). Densitometry was performed by scanning the films (ScanJet IIcx, Hewlett-Packard Co.) and then analyzing the images using Scion Image software (Frederick, MD). The protocol for phospho-specific and control MAPK was the same except that the dilution of the first antibodies were 1:1000 and 1:5000, respectively, and that the incubation with the first antibodies was at room temperature for 2 h. For PKC, cell lysates or cytosolic and membrane fractions were separated by 7.5% SDS-PAGE. The dilution of the antibodies against PKC isoforms were 1:500 for PKC-␣, -␤I, -␤II, -␦, -⑀, -␥, -, -, and -and 1:2000 for PKC-.
PI3 kinase assay
Confluent cells in 10-cm plates (Falcon) were washed with serum-free medium and kept in the SFM overnight before stimulation with indicated concentrations of IGF-I for 10 min. After IGF-I stimulation, cells were lysed with lysis buffer (1% IGEPAL CA-630, 137 mm NaCl, 1 mm MgCl 2 , 1 mm CaCl 2 , 150 m vanadate, 1 g/ml leupeptin, and 1 g/ml aprotinin). The PI3 kinase assay was performed as described previously (20) with some modifications. Briefly, equal amounts of cell lysates were incubated with specific IRS-I antibody overnight at a 1:500 dilution and the immune complexes were precipitated by protein A-Sepharose. The pellets were resuspended in 50 l of PI3 kinase buffer (20 mm Tris, pH 7.5, 100 mm NaCl, 0.5 mm EGTA) and 10 g of phosphatidylinositol was added followed by 10 Ci of [ 32 P]ATP. After a 10-min reaction at room temperature, lipids were extracted using 160 l of MeOH:CHCl 3 (1:1). The extracts were spotted on 1% potassium oxalate-treated TLC plates (Analtech, Newark, DE) and developed in CHCl 3 :MeOH:NH 4 OH (75: 58:17, vol/vol/vol). The highest migrating spots on the TLC plate, representing phosphatidylinositol phosphate, were quantitated by performing densitometry as described above.
Protein kinase C assay
Subconfluent cells cultured in 12-well plates (Falcon) were washed with 1x PBS for three times and total cellular extracts were prepared by sonicating in an extraction buffer containing 25 mm Tris-HCl (pH 7.5), 250 mm sucrose, 0.5 mm EDTA, 0.5 mm EGTA, 20 g/ml leupeptin, 2 g/ml aprotinin, and 1 mm DTT (21) . The extracts were cleared by centrifuging (8,000 ϫ g) for 10 min at 4 C and PKC activity was determined immediately using the method of Yasuda et al. (22) with some modification. Briefly, phosphorylation of the PKC-specific substrate peptide, Ac-MBP (4 -14) , was carried out in 50 l assay buffer containing 20 mm Tris-HCl (pH 7.5), 20 mm MgCl 2 , 1 mm CaCl 2 , 20 m ATP, 0.25 Ci [␥-
32 P]ATP, 50 m Ac-MBP (4 -14), 10 m phorbol 12-myristate 13-acetate (PMA), 280 g/ml phosphatidyl serine, 0.3% Triton-X 100 plus 25 l cellular extract in the presence or the absence of the PKC pseudosubstrate inhibitor peptide, PKC (19 -36) (25 m). The mixture was incubated for 5 min at 30 C and a 25 l aliquot was spotted onto a P-81 phosphocellulose membrane. The membrane was washed twice with 1% H 3 PO 4 followed by two more washes with water and the membrane-bound radioactivity was counted by liquid scintillation counter. Specific PKC activity was calculated by subtracting the nonspecific activity in the presence of PKC (19 -36) from the total activity and expressed as pmol 32 P bound to Ac-MBP per min per mg protein. PMA, a PKC regulator, and GF109203X, a PKC specific inhibitor, were used to down-regulate total cellular PKC activity. To determine concentrations and time required by PMA and GF109203X to down-regulate PKC activity, cells were washed five times with SFM and then incubated in SFM containing either PMA (0.1-1000 nm) or GF109203X (0.02-200 m) for up to 24 h. At each time point, the activity was expressed as percentage of the activity that has been treated with SFM only. To examine the effects of PKC down-regulation on IGF-I actions, cells were starved for 18 -24 h with SFM and incubated for 2 h in SFM with indicated concentrations of either PMA or GF109203X before growth factor treatment.
RNA isolation and Northern blot analysis
Total RNA was isolated from cell cultures using TriReagent following the manufacturer's instructions (Molecular Research Center, Inc., Cincinnati, OH) and was quantified by measuring UV absorption at O.D. 260 nm. RNA samples were size-fractionated on a 1.0% agarose gel, blotted and fixed onto a Hybond-N membrane (Amersham Pharmacia Biotech, Amersham, UK). They were hybridized with the [ 32 P] dCTP labeled IGFBP and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) complementary DNAs (cDNAs) (23) . Densitometry was performed as described above.
[ 3 H]-thymidine incorporation assay
To determine the rate of DNA synthesis, cells were plated onto 96-well plates (Falcon) at 15,000 cells/well in DMEM supplemented with 10% FBS and incubated for 3-5 days without a medium change. After washing three times with serum-free DMEM, the cultures were exposed to DMEM that contained 1 Ci 
Cell migration assay
VSMC were grown to confluence on six-well plates (Falcon). The confluent monolayers were wounded with a single razed blade as described previously (24) . The plate was rinsed once and incubated in DMEM plus 0.2% FBS with indicated concentrations of IGF-I and/or PMA for 2 days at 37 C. After the incubation, the number of cells migrating across the wound area was determined. Each data point represents a mean of seven to ten 1-mm regions that were selected immediately after wounding.
Statistical analysis
One-way ANOVA followed by Fisher PLSD test was used to compare differences between control and test groups. Values are means Ϯ se.
Results

IGF-I alters the subcellular distribution of several PKC isoforms in porcine VSMCs
PKC is a family of cytoplasmic phosphorylating enzymes consisting of at least 11 members which can be categorized into conventional (c) PKC (␣, ␤I, ␤II, and ␥), novel (n) PKC (␦, ⑀, , ) and atypical (a) PKC (, , ) (25) . These PKC isoforms are subject to differential tissue distribution and may have distinct functions. For instance, PKC-␦ is growth inhibitory, whereas PKC-⑀ exerts transforming activity when overexpressed (26, 27) . To elucidate the possible role(s) of PKC in IGF-I signaling, we first examined the specific PKC isoforms expressed in porcine VSMCs by Western immunoblot analysis. The results are summarized in Table 1 . Seven PKC isoforms, namely PKC-␣, -␤I, -⑀, -, -, , and -, were detectable in porcine VSMCs. No specific signal was detected for PKC-␤II, -␦ and -␥ in these cells.
Activated PKC is known to be translocated from cytosol to membrane (25) . To test which of these PKC isoenzymes are regulated by IGF-I, the cytosolic and membrane fractions were prepared from the serum-starved and IGF-I-stimulated porcine VSMCs, and the possible membrane translocation was examined for each of these PKCs. Because PMA is a potent regulator for cPKCs and nPKCs, cells treated with various concentrations of PMA were used as controls. As shown in Figs. 1A and 2A, the two detectable cPKC isoforms, PKC-␣ and -␤I, were predominantly found in the cytosolic fraction in the serum-starved, resting cells. As expected, PMA dose dependently stimulated membrane translocation of PKC-␣. At the concentration of 1 m PMA, the majority of PKC-␣ (ϳ90%) was detected in the membrane fraction ( Fig.  2A) . A notable effect of PMA on PKC-␤I levels was also detected. The cytosolic levels of PKC-␤I decreased to undetectable level at the high concentration (1 m), while low concentration of PMA (0.1 nm) increased the levels of cyto- Cells were serum-starved overnight prior to the IGF-I treatment (100 ng/ml). The cells were lysed, and the cytosolic and membrane fractions were prepared. Equal amounts of protein from each fraction were separated by 7.5% SDS-PAGE and subjected to Western analysis as described in Materials and Methods. ND, Not detected.
solic PKC-␤I (Fig. 1A) . Of the two cPKC isoforms, only PKC-␤I was regulated by IGF-I (Fig. 1B) . This regulation appeared to be transient. IGF-I (100 ng/ml) significantly increased the cytosolic levels of PKC-␤I at 30 min (P Ͻ 0.05, n ϭ 3) (Fig. 1B) . No significant change was observed at earlier or later time points. IGF-I did not affect the subcellular distribution of PKC-␣ throughout the experiment (Fig. 2B) .
IGF-I treatment also altered the subcellular distribution of Equal amounts of protein from each fraction were separated by 7.5% SDS-PAGE and subjected to Western immunoblot using antibodies specific for each of the PKC isoforms; B, Effects of IGF-I on the subcellular distribution PKC-␤I, -⑀, -, and -. Cells were treated with IGF-I (100 ng/ml) for time indicated, and the cytosolic and membrane fractions were prepared.
Western immunoblot was performed as described above.
FIG. 2. IGF-I does not change the subcellular distribution of PKC-␣ or -in cultured porcine VSMCs. A, Effects of PMA on the subcellular distribution of PKC-␣ and -. After PMA (0.1 nM, 1 nM or 1 M) treatment, the cytosolic (C) and membrane (M) fractions were prepared as described in Materials and Methods. Equal amounts of protein from each fraction were separated by 7.5% SDS-PAGE and subjected to Western immunoblot using specific antibodies; B, Effects of IGF-I on the subcellular distribution PKC-␣ and -. Cells were treated with IGF-I (100 ng/ml) for time indicated, and the cytosolic and membrane fractions were prepared. Western immunoblot was performed as described above.
two out of the three nPKC isoforms, PKC-⑀ and - (Fig. 1B) . PKC-⑀ was present predominantly in the membrane fraction in serum-starved, resting cells (70%). When treated with 1 m PMA, the cytosolic levels of PKC-⑀ decreased to 38% of the control levels (P Ͻ 0.05, n ϭ 5) and its membrane levels showed a consistent increase, although this increase was not statistically significant (Fig. 1A) . IGF-I (100 ng/ml) treatment decreased the cytosolic PKC-⑀ by 33% at 10 min (P Ͻ 0.05, n ϭ 4) and 22% at 120 min (P Ͻ 0.05, n ϭ 4) and caused a consistent but statistically insignificant increase in the membrane fraction at these same time points (Fig. 1B) . No significant change was detected at 2, 5, or 30 min after IGF-I treatment. PKC-was most abundant in the cytosol fraction (Ͼ 90%) in serum-starved, resting cells. In two out of the three experiments performed, the cytosolic levels of PKCwere reduced by 30% with PMA (1 nm or 1 m), and the membrane levels were increased by 5.5-fold (1 nm) and 2.4-fold (1 m), respectively (Fig. 1A) . In all three experiments, IGF-I treatment resulted in a significant increase in the membrane PKC-levels at 10 and 30 min (P Ͻ 0.05) (Fig. 1B) . As predicted, the subcellular distribution of PKC-and PKC-, two atypical PKCs expressed in porcine VSMCs, was unchanged by PMA (Figs. 1A and 2A ). IGF-I had no effect on the distribution of PKC- (Fig. 2B) . In contrast, IGF-I treatment caused a 2-fold increase in the membrane fraction levels of PKC-at 30 min. These results indicate that IGF-I stimulation altered the subcellular distribution or concentration of several PKC isoforms including PKC-␤I, -⑀, -, and -, in primary cultured porcine VSMCs.
Down-regulation and inhibition of PKC abolish IGF-Idependent VSMC proliferation, migration and IGFBP-5 gene expression
To determine the possible role(s) of PKC in IGF-I signaling, PMA was used to down-regulate PKC activity in these cells. Because PMA can either activate or down-regulate PKC depending on concentrations and cellular context, the concentration-and time-dependent effects of PMA on total cellular PKC activity in cultured porcine VSMCs were determined first. The total cellular PKC activity of fed cells was 158.5 Ϯ 20.9 pmol 32 P/min/mg (n ϭ 12). Serum-starvation of the cells for 5 min significantly decreased the activity to 73.2 Ϯ 33.9 32 P/min/mg (n ϭ 3) (P Ͻ 0.05). Further starvation up to 24 h did not cause an additional decrease. As shown in Fig. 3 , treatment of VSMCs with low concentrations of PMA (0.1 and 1 nm) resulted in a transient increase in PKC activity. At 5 and 10 min after incubation, PMA at 0.1 nm caused 184 Ϯ 61% and 146 Ϯ 39% increases, respectively. The activity returned to the basal level after 3 h. Similarly, up-regulation by PMA (1 nm) was greatest at 5 and 10 min (206 Ϯ 45% and 129 Ϯ 20%, respectively) and returned to the initial basal level after 30 min. 10 nm of PMA resulted a transient up-regulation in two out of three experiments. After 30-min incubation, it led to a modest down-regulation of PKC activity (69% inhibition). In contrast, treatment of cells with 1 m PMA for 5 min decreased the activity to 34 Ϯ 7% (n ϭ 3) of the control. After 30 min, 1 m PMA resulted in a 97% inhibition and this inhibition was sustained for 24 h (Fig. 3) . These results indicate that, within the time range tested, PMA activates total PKC activity at concentrations below 10 nm but down-regulates PKC activity at concentrations higher than 1 m.
Although PMA is a potent regulator of cPKC and nPKC, it does not regulate aPKC activity (25) . We therefore tested the effect of GF109203X, a bisindolylmaleimide, which has been shown to inhibit the activity of all three types of PKCs by competing for the ATP binding site (28, 29) . As shown in Fig. 4A , GF109203X caused a dose-dependent decrease in total PKC activity in porcine VSMCs. The estimated IC 50 value was 3.6 m in porcine VSMCs, which is comparable with the reported IC 50 values for this inhibitor (8.4 nm to 5.8 m) (28, 29) . At 20 m, it resulted in a 90 Ϯ 1% inhibition (n ϭ 2). The inhibitory effect of GF109203X occurred within 5 min and lasted for at least 24 h (Fig. 4B) .
We next examined the possible role(s) of PKC in mediating the IGF-I-stimulated DNA synthesis in porcine VSMCs by incubating cells with IGF-I in the absence or presence of PMA and/or GF109203X. As shown in Fig. 5 , IGF-I stimulated 3 H-thymidine incorporation in a dose-dependent manner. At 10 ng/ml, IGF-I induced a maximum increase of 236% (P Ͻ 0.01). When PMA (1.6 m), which nearly completely suppressed PKC activity in this system, was added, the IGF-Istimulated increase in 3 H-thymidine incorporation was negated. Similarly, inhibition of PKC activity by 10 m GF109203X abolished IGF-I-stimulated DNA synthesis (Fig.  5) . PMA (1.6 m) or GF109203X (10 m) alone resulted in a 37% and 49% decreases in thymidine incorporation, respectively. In contrast, PMA at 16 nm, resulted in a moderate increase and this effect was additive with IGF-I in stimulating 3 H-thymidine incorporation (Fig. 5 ). When 10 m of GF109203X, which inhibits binding of ATP to PKC, was added together with 16 nm PMA in the presence and absence of IGF-I, it inhibited both the PMA (16 nm) and IGF-I-induced increases. This result indicates that the increased DNA synthesis with PMA (16 nm) is due to its transient up-regulation of PKC. We then sought to determine the effect of blocking PKC activity in IGF-I-stimulated VSMC migration. For this, cells were incubated with IGF-I in the presence or absence of a high concentration of PMA (1 m). When porcine VSMCs were not stimulated by IGF-I, 11.9 Ϯ 5.7 cells/field migrated. As shown in Fig. 6 , IGF-I (100 ng/ml) induced a 3.6-fold increase in cell migration (P Ͻ 0.01). In comparison, PDGF (20 ng/ml), the strongest known chemoattractant for VSMCs, caused a 6.7-fold increase while no increase was observed with 500 ng/ml of angiotensin II. Incubation of the cells with 1 m PMA alone did not significantly alter the basal migration levels, but it completely abolished the IGF-I-induced increase (Fig. 6) .
To further establish that PKC activity is involved in IGF-I actions, we examined the effect of PKC down-regulation on IGF-I-induced gene expression. Our previous study has shown that IGFBP-5 gene is a transcriptional target of IGF-I in this cell type (11) . As shown in Fig. 7 , treatment of porcine VSMCs with IGF-I (100 ng/ml) resulted in a 123-fold increase in the steady-state levels of IGFBP-5 messenger RNA (mRNA) (n ϭ 3). There was no significant change in the levels of IGFBP-2 mRNA or GAPDH mRNA. Down-regulation of PKC activity with 1 m PMA abolished this IGF-I-induced 6 . Down-regulation of PKC activity abolishes IGF-I-dependent porcine VSMC migration. Confluent monolayers were wounded and then incubated with IGF-I (100 ng/ml) in the absence or presence of PMA (1.6 M) as described in Materials and Methods. For positive and negative controls, the cells were incubated with PDGF-BB (20 ng/ml) and Angiotensin II (ANG II) (500 ng/ml), respectively. After incubation, the number of cells migrating across the wound area was determined. Values are the means Ϯ SE of fourteen to sixteen replicates in three separate experiments.
increase in IGFBP-5 expression. To ascertain that the change to IGF-I was not due to any toxic effect of PMA, we examined its effect on the forskolin-induced IGFBP-5 gene expression. Our previous results indicated that forskolin treatment increases IGFBP-5 gene expression through a cAMP-mediated mechanism (11) . As shown in Fig. 7 , forskolin (10 m) treatment resulted in a 86-fold increase in IGFBP-5 mRNA abundance, and the effect was additive with IGF-I-induced IGFBP-5 gene expression, suggesting that they may act through different mechanisms. When PMA (1 m) was added with forskolin, it did not significantly affect its induction of IGFBP-5 gene expression. Likewise, the response to IGF-I plus forskolin was reduced by PMA to the same level as forskolin alone (Fig. 7) indicating that only IGF-I induced expression was inhibited by the treatment.
Down-regulation and inhibition of PKC activity do not affect IGF-I-induced PI3 kinase activation
Because we have previously shown that IGF-I stimulates IGFBP-5 gene expression via the PI3 kinase signaling pathway in porcine VSMCs (18), we wondered whether regulation of PKC activity could affect IGF-I-induced PI3 kinase activation. For this, cells were pretreated with PMA (0.1 nm or 1 m) or GF109203X (20 m) for 2 h before a 10-min exposure to IGF-I (50 ng/ml). The cells were lysed and immunoprecipitated with anti IRS-1 antibody. The activity of PI3 kinase associated with IRS-I was determined by an in vitro PI3 kinase using phosphatidylinositol as substrate and activity (Fig. 8) . The effect of IGF-I on the phosphorylation status of PKB/Akt, a downstream target of PI3 kinase, was also examined using phospho-specific and control PKB/Akt antibodies. As shown in Fig. 9A , neither PMA nor GF109203X had any significant effect on IGF-I-stimulated PKB/Akt phosphorylation. PMA or GF109203X alone did not change the basal level, either. These data suggest that down-regulation and inhibition of total PKC activity do not affect the IGF-I-induced activation of PI3 kinase and PKB/Akt.
Because it is known that certain PKC isoforms can activate MAPK in VSMCs (30), we examined the potential effects of PMA and GF109203X treatments on IGF-I-dependent MAPK phosphorylation. Treatment of cells with PMA at 0.1 nm and 1 m caused a moderate increase in MAPK phophorylation (Fig. 9B) . This increase was additive to the IGF-I-induced MAPK phophorylation. In contrast to PMA, treatment of porcine VSMCs with GF109203X (20 m) resulted in a modest decrease in IGF-I-induced MAPK phosphorylation (Fig.  9B) . GF109203X treatment alone resulted in a decline in basal MAPK phosphorylation. These opposite effects of PMA (1 m) and GF109203X (20 m) suggest that these drugs have different effects on MAPK activation, either independent of PKC or through their differential regulation of c, nPKC and aPKC.
Discussion
The results of this study have shown that PKC-␣, -␤I, -⑀, -, -, -, and -are expressed in cultured procine VSMCs. Of these PKC isoforms, the subcellular distribution or concentration of PKC-␤I, -⑀, -, and -is regulated by IGF-I. Furthermore, up-regulation of PKC activity enhanced the IGF-I-stimulated DNA synthesis, whereas down-regulation or inhibition of PKC inhibited IGF-I-stimulated VSMC DNA synthesis, migration, and IGFBP-5 gene expression. These data indicate that PKC may be involved in mediating the biological responses of VSMCs to IGF-I in primary cultured procine VSMCs. Our data also indicate that inhibition or down-regulation of PKC does not affect IGF-I-induced PI3 kinase and PKB/Akt activation, suggesting that these PKC isoforms either act independently of the PI3 kinase pathway or act further downstream of PKB/Akt in the IGF signaling network.
Five PKC isoforms, including PKC-␣, -␤, -␦, -⑀ and -, have been previously reported in rodent and human VSMCs (26, 30, 31) . In the present study, we have identified PKC-and -in cultured primary porcine VSMCs in addition to previously reported PKC-␣, -␤, -⑀ and -. Contrary to a previous study in rat VSMCs (31), we failed to detect any specific signal for PKC-␦. This may be due to differences that exist among mammalian species. The possible effect(s) of IGF-I in regulating these PKC isoforms has not been well studied in this cell type. To date, there is only one published observation showing that IGF-I stimulation causes membrane translocation of PKC-⑀, but not that of PKC-␣, -␤, and -␦ in rat VSMCs (31) . In good agreement with this report (31), we found that IGF-I stimulation caused transient but significant decrease in cytosolic PKC-⑀ levels in porcine VSMCs. This decrease in cytosolic PKC-⑀ was associated with a consistent but statistically insignificant increase in its membrane presence, suggesting the subcellular distribution of PKC-⑀ is also regulated by IGF-I in the porcine system. Furthermore, the present study demonstrates that IGF-I also stimulated the membrane translocation of PKC-and -and regulated the cytosolic levels of PKC-␤I in this cell type. These effects of IGF-I are specific because IGF-I did not affect subcellular distribution of PKC-␣, -, whereas PMA induced the membrane translocation of PKC-␣ in cultured porcine VSMCs. Therefore, not only PKC-⑀ but PKC-␤I, -and -are also regulated/activated by IGF-I and may be involved in IGF-I signaling in VSMCs.
Several mechanisms may underlie this IGF-I-regulated translocation of PKC-␤I, -⑀, -, and -. A recent study using Swiss 3T3 mouse fibroblasts indicated that diacylglycerol (DAG) production stimulated by IGF-I via activating phosphatidyl inositol-phospholipase C (PI-PLC) may be the driving force for PKC translocation, which in turn leads to cell proliferation (32) . In VSMCs, IGF-I has been shown to regulate DAG production and cytosolic Ca 2ϩ influx (33) . DAG is an allosteric PKC activator produced endogenously which binds to the C1 domain of cPKCs and nPKCs. The domain contains a Cys-rich motif that forms the DAG/phorbol ester binding site and serves as hydrophobic anchor to recruit PKC to membrane. Membrane binding is followed by enzyme activation (25) . It is possible that the 3 c-and nPKCs (i.e. PKC-␤I, -⑀, and -) may be regulated by IGF-I through this mechanism in VSMCs.
While the activity of both Ca 2ϩ -sensitive cPKC (␣, ␤I, ␤II, and ␥) and Ca 2ϩ -insensitive nPKC (␦, ⑀, , ) are regulated by their DAG/phorbol ester binding sites, aPKCs including PKC-, -, -are not (25) . Another mechanism that IGF-I may use to regulate PKC is the activation of PI3 kinase. Several reports indicate that the products of PI3 kinase including phosphatidylinositol 3,4,5-trisphosphate are capable of activating PKC-and -⑀ (34 -36) . In agreement with these observations, a recent study in human HL-60 promyeloid cells indicated that PKC-is a downstream target of PI 3-kinase that is activated during IGF-I-promoted macrophage differentiation (37) . Intriguingly, IGF-I-induced PI3 kinase activation has been shown to be critical in maintaining a differentiated phenotype in cultured chick Gizzard SMCs (38) . As we have shown in this and a previous study (18) , IGF-I stimulation strongly activates PI3 kinase in porcine VSMCs. In addition, PKC-is translocated to the membrane fraction in IGF-I treated cells following the activation of PI3 kinase. Experiments are currently underway to determine whether specific inhibition of IGF-I-induced PI3 kinase activation will abrogate the IGF-I-induced PKC-translocation.
Activation of PKC by IGF-I has been previously documented in fibroblasts, chondrocytes, myocytes, astrocytes, and VSMCs (30, 39 -42) . However, the biological consequences of the activation is not well understood. In rat astrocytes, inhibition of PKC activity attenuates but does not abolish the IGF-I-stimulated DNA synthesis (42) . A recent study using rat VSMCs demonstrated that inhibition of PKC by a specific inhibitor, RO31-8220, reduced IGF-I-stimulated migration, whereas long-term incubation with PMA (100 nm), which presumably down-regulated PKC, had little effect (43) . In contrast, it was reported that IGF-I-induced proliferation of neonatal bovine VSMCs was unaffected by another PKC inhibitor, dihydrosphingosine (44) . It should be noted that, in these previous studies, it was not determined whether the PKC activity was actually effectively inhibited by these drugs. PMA is a member of phorbol esters that are structurally related to DAG. PMA can both up-and downregulate PKC activity depending on the dose, time, and cellular context. In the present study, we examined the doseand time-dependent regulation of PKC activity by PMA in cultured VSMCs for the first time. Our data indicate that PMA can either up-regulate or down-regulate PKC activity with the threshold being ϳ10 nm. PKC activation by the low concentrations of PMA is most apparent at 5 min and is followed by a time-dependent loss of activity. This time course data are consistent with a previous observation made in GH 3 cells indicating that the maximum membrane translocation of PKC induced by PMA happened at 15 min, followed by a time-dependent degradation of the membraneassociated enzyme (45) . PMA at a higher concentration (1 m) causes a nearly complete suppression of PKC activity (ϳ97%), and this effect is long lasting. In addition to PMA, GF109203X, a drug that has been shown to inhibit all PKC isoforms (28, 29) , was also used to inhibit PKC activity. While PMA down regulates PKC by increasing its turnover through stimulation of membrane association, GF109203X inhibits PKC by competing for the ATP binding site (28, 45) . We determined that the IC 50 value of GF109203X is 3.6 m in cultured procine VSMCs. At the concentration of 20 m, it led to a more than 90% inhibition. When the total PKC activity is suppressed by either high concentrations of PMA or inhibited by GF109203X, the IGF-I-stimulated VSMC migration and DNA synthesis were completely negated. In addition, down-regulation of PKC activity by 1 m PMA completely abolished the IGF-I-induced IGFBP-5 expression. This effect was specific because no change was detected in the expression of IGFBP-2 and GAPDH. The effect of PMA or GF109203X is probably not due to any nonspecific toxic effect of these drugs, because 1) they did not abolish the mitogenic activity of FBS in these cells (data not shown); 2) PMA did not affect c-AMP activated IGFBP-5 gene expression; and 3) PMA treatment did not change the basal levels of cell migration. These data, together with the observation that the subcellular distribution of PKC-␤I, -⑀, -, and -are regulated by IGF-I strongly support the proposition that these PKC isoforms may be essential signaling intermediates for IGF-I in VSMCs. Because our results show that down-regulation of PKC by PMA completely inhibits IGF-I-stimulated DNA synthesis, migration, and gene expression, we believe that either PKC-␤I, -⑀, -alone or in combination rather than the atypical PKC-is involved in these actions of IGF-I in porcine VSMCs. Further studies are needed to determine the specific role(s) for each of these PKC isoforms by overexpression or antisense inhibition approach in porcine VSMCs. The physiological consequence of the IGF-I-induced PKC-is yet to be determined in VSMCs. As discussed earlier, PKC-is a downstream target of PI 3-kinase and is involved in the action of IGF-I on cell differentiation in other cell types. Because IGF-I-induced PI3 kinase activation has been implicated in maintaining a differentiated phenotype in cultured chick Gizzard SMCs (38) , it would be interesting to determine whether a similar mechanism operates in VSMCs.
Recently, we have shown that specific inhibition of IGF-I-induced PI3 kinase activation, but not MAPK activation, abolished the IGF-I-stimulated DNA synthesis and IGFBP-5 gene expression in porcine VSMCs, indicating that the activation of PI3 kinase but not MAPK is essential for IGF-I actions in these cells (18) . In the present study, we further explored possible "cross-talk" between the IGF-I-induced PKC activation and other pathways of the IGF signaling network. The results indicate that down-regulation or inhibition of PKC has no significant effect on the IGF-I-induced PI3 kinase activation. Similarly, no significant effect was found on the IGF-I-induced PKB/Akt phosphorylation. These data indicate that PKC is probably not involved in the IGF-I-induced PI3 kinase activation, suggesting that these PKC isoform(s) act either further downstream of PKB/Akt or independently from the PI3 kinase pathway. In contrast to its inability to affect PI3 kinase, both low and high concentrations of PMA induced the phosphorylation of MAPK in porcine VSMCs. This is not surprising because PMA has been shown to cause MAPK activation in a number of cell types (19, 46) . A recent study using monkey kidney indicates that activation of PKC can stimulate ras (47) . The activated ras, in turn, stimulates the small G protein-coupled, raf, MEK, and ultimately MAPK. Therefore, IGF-I and PMA may have acted via separate mechanisms to produce an additive effect on MAPK phosphorylation. Unlike PMA, inhibition of PKC by GF109203X reduced the basal and IGF-I-stimulated phosphorylation of MAPK. It is of interest that high concentrations of PMA abolished IGF-I-stimulated DNA synthesis and IGFBP-5 gene expression while activating MAPK in porcine VSMCs. This study further supports our conclusion that MAPK activation is not required for IGF-I-stimulated IGFBP-5 gene expression in porcine VSMC (18) .
In summary, the results of this study has shown that several PKC isoenzymes, including PKC-␤I, -⑀, -, and -are regulated by IGF-I, and that PKC activity is required for IGF-I-induced migration, DNA synthesis and gene expression in porcine VSMCs. Therefore, these PKC isoforms may be essential signaling intermediates for IGF-I acting either independently from the PI3 kinase pathway or downstream of PKB/Akt in the IGF signaling network in VSMCs. Further studies will focus on the specific role(s) of these PKC isoforms in IGF-I signaling and how they work together with other signaling intermediates to specify the cellular responses to the plieotropic IGF-I. By identifying the specific role(s) of each of these PKC isoform, insight may be gained of how IGF-I regulates VSMC proliferation, migration, and apoptosis and how it contributes to VSMC hyperplasia associated with the development of atherosclerotic lesions.
